DNA

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company,…

2 months ago

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

GAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S.…

2 months ago

ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19

UNIONDALE, NY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation…

2 months ago

Rakovina Therapeutics’ President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit

VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a…

2 months ago

AI in Personalized Nutrition Market to Reach USD 4.26 Billion by 2032, Driven by Predictive Analytics, Deep Learning & Real-Time Dietary Intelligence | DataM Intelligence

AUSTIN, Texas and TOKYO, Nov. 17, 2025 /PRNewswire/ -- According to DataM Intelligence, the AI in Personalized Nutrition Market Size reached…

2 months ago

OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma

OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in…

2 months ago

Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy

Company to host investor conference call and webcast on Monday, November 17th, at 9:00am ESTPITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE)…

2 months ago

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

–Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study…

2 months ago

Volta Labs and New England Biolabs Partner to Expand Automated NGS Library Preparation on the Callisto Platform

BOSTON, Nov. 14, 2025 /PRNewswire/ -- Volta Labs, a leader in automation for genomics, and New England Biolabs® (NEB®), a world-renowned…

2 months ago

New England Biolabs® launches the NEBNext® Flu A Integrated Indexing Primer Module to advance Influenza A surveillance and sequencing

Streamlined, high-throughput sequencing of Influenza A virus with integrated indexing for Oxford Nanopore Technologies® platforms IPSWICH, Mass., Nov. 13, 2025…

2 months ago